《新股表现》德视佳(01846.HK)半日收11.8元 高上市价57%
德视佳(01846.HK)暗盘高见13元,收12.88元,高上市价72%;该股首挂高开89%报14.2元,最多飙升1倍至15.18元遇阻,曾回顺至10.8元,半日收11.8元,较上市价7.5元,高57%,半日成交7,678万股,涉资9.93亿元。
德视佳主要於德国、丹麦及中国从事视力矫正业务。是次来港上市共发售7,933.4万股,其中10%公开发售获41倍超购,已启动回拨机制占比至30%,认购一手中签率30%;股份以招股范围(6.2-8.8元)中间位定价,料集资净额5.27亿元,主要用作包括成都和重庆等内地主要城市设立诊所、潜在收购欧洲诊所集团及加大营销力度等。上市独家保荐人中银国际亚洲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.